Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06570447
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-11
Brief Title:
Glofitamab Combination With Chidamide in Patients With RecurrentRefractory DLBCL
Sponsor:
None
Organization:
None
Study Overview
Official Title:
An Open-label Single-arm Single-center Phase II Clinical Trial of Glofitamab Combination With Chidamide in Patients With Recurrent and Refractory Diffuse Large B-Cell Lymphoma
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
An open-label single-arm single-center phase II clinical trial to evaluate the feasibility efficacy and safety of Glofitamab Combination with chidamide in patients with recurrentrefractory diffuse large B-cell lymphoma
Detailed Description:
This is an open-label single-arm single-center study to evaluate the feasibility efficacy and safety of Glofitamab Combination with chidamide in the patient 18 years of age with recurrentrefractory diffuse large B-cell lymphoma Subjects who meet the eligibility criteria will receive combination therapy of Glofitamab chidamide The study will include the following sequential phases screening treatment and follow-up
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None